Synapse - Neha Korde

Results (237)

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma

Journal Article

Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
British Journal of Haematology (2020)

Fulltext@MSK | Save

Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma

Research Letter

Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
Clinical Lymphoma, Myeloma and Leukemia (2020)

Fulltext@MSK | Save

VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis

Meeting Abstract

Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
Blood (2019)

Fulltext@MSK | Save

An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma

Meeting Abstract

Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
Blood (2019)

Fulltext@MSK | Save

A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)

Meeting Abstract

Manasanch, E. E.; Jagannath, S.; Lee, H. C.; Patel, K. K.; Graham, C.; Kaufman, G. P.; Thomas, S. K.; Iyer, S.; Mailankody, S.; Korde, N.; more...
Blood (2019)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Using current clinical markers to define high risk smoldering multiple myeloma: Agree to disagree

Meeting Abstract

Hill, E.; Korde, N.; Mailankody, S.; Morrison, C.; Dew, A.; Albert, J. H.; Graap, K.; Maura, F.; Landgren, O.; Kazandjian, D.
Blood (2019)

Fulltext@MSK | Save

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma

Meeting Abstract

Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
Blood (2019)

Fulltext@MSK | Save

MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy